MLD is the sole owner of intellectual property relating to the measurement of gastric tract acids (GTAs) for determining colorectal and pancreatic cancer risk, and for the measurement of plasmalogen phospholipids as a risk factor for Alzheimer’s disease and related dementias, and other neurological conditions. MLD currently manufactures and sells tandem mass spectrometry kits for these panels that can be run on any conventional triple quadruple mass spectrometer, or processed in our certified laboratory. Learn more below.
GTA-446 test kit
Gastric tract acids (GTAs) are long chain fatty acid metabolites in the blood that were discovered and patented by MLD scientists to be reduced in the circulation of colorectal cancer patients. GTA-446 is a 28-carbon GTA that has high sensitivity and specificity for colorectal cancer. MLD has now translated this knowledge into a commercially available screening test that can be used to determine risk of CRC. Learn more and order your test kits here.
PC-594 test kit
PC-594 is a circulating 36-carbon gastric tract acid (GTA) that was discovered and patented by MLD scientists to be deficient in pancreatic cancer patients. A PC-594 deficiency is therefore associated with increased risk of pancreatic cancer. The PC-594 test kit can now be used to determine increased risk of pancreatic cancer by any lab with tandem mass spectrometry capabilities. Learn more and order your test kits here.
Plasmalogen Index
An abnormally low plasmalogen level is a risk factor for Alzheimer’s disease. MLD’s Plasmalogen Index test is the first commercially validated assay that quantitatively measures multiple plasmalogen species in a biological sample. Learn more here.